Takayuki Yoshimoto Selected Research

CD5 Antigens

11/2021	Author Correction: IL-23p19 and CD5 antigen-like form a possible novel heterodimeric cytokine and contribute to experimental autoimmune encephalomyelitis development.
1/2021	IL-23p19 and CD5 antigen-like form a possible novel heterodimeric cytokine and contribute to experimental autoimmune encephalomyelitis development.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Takayuki Yoshimoto Research Topics

Disease

27	Neoplasms (Cancer) 01/2021 - 07/2003
9	Infections 01/2018 - 01/2005
8	Inflammation (Inflammations) 05/2017 - 03/2005
7	Melanoma (Melanoma, Malignant) 07/2014 - 06/2006
5	Carcinoma (Carcinomatosis) 04/2012 - 02/2004
4	Rheumatoid Arthritis 01/2013 - 01/2005
4	Hepatocellular Carcinoma (Hepatoma) 05/2009 - 03/2003
4	Necrosis 05/2005 - 04/2004
3	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 11/2021 - 01/2013
3	Lymphoma (Lymphomas) 01/2015 - 12/2003
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2014 - 09/2013
3	Hepatitis 01/2013 - 03/2010
2	Colitis 01/2022 - 01/2013
2	Psoriasis (Pustulosis Palmaris et Plantaris) 05/2017 - 01/2012
2	Autoimmune Diseases (Autoimmune Disease) 01/2016 - 12/2009
2	Neoplasm Metastasis (Metastasis) 01/2015 - 06/2006
2	Asthma (Bronchial Asthma) 10/2012 - 10/2007
2	Respiratory Hypersensitivity 10/2012 - 10/2007
1	Pain (Aches) 01/2022
1	Azoospermia 01/2022
1	Stroke (Strokes) 07/2021
1	Cerebral Hemorrhage 07/2021
1	Hypertensive Intracranial Hemorrhage 07/2021
1	Headache (Headaches) 07/2021
1	Hypertension (High Blood Pressure) 07/2021
1	Macular Edema 07/2021
1	Drug Resistant Epilepsy 01/2021
1	Acute Liver Failure (Fulminant Hepatic Failure) 01/2019
1	Communicable Diseases (Infectious Diseases) 01/2018
1	Hyperplasia 05/2017
1	Malaria 03/2016
1	Thymus Neoplasms (Thymus Neoplasm) 01/2015
1	Residual Neoplasm 01/2014
1	Lung Neoplasms (Lung Cancer) 04/2012
1	Skin Diseases (Skin Disease) 01/2012
1	Arthritis (Polyarthritis) 08/2011

Drug/Important Bio-Agent (IBA)

21	Interleukin-27 (Interleukin 27)IBA 01/2018 - 02/2004
12	CytokinesIBA 11/2021 - 09/2004
10	Interleukin-17 (Interleukin 17)IBA 01/2022 - 09/2007
9	Interleukin-23 (Interleukin 23)IBA 05/2017 - 06/2006
4	Interleukin-12 (IL 12)IBA 01/2016 - 03/2005
4	OsteopontinIBA 05/2005 - 04/2004
3	InterferonsIBA 01/2018 - 04/2004
3	InterleukinsIBA 05/2017 - 02/2004
3	Imatinib Mesylate (Gleevec)FDA Link 01/2014 - 09/2013
3	Interleukin-22 (IL-22)IBA 01/2013 - 03/2010
3	Complementary DNA (cDNA)IBA 08/2006 - 09/2003
2	CD5 AntigensIBA 11/2021 - 01/2021
2	Interleukin-23 Subunit p19IBA 11/2021 - 01/2021
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 07/2021 - 06/2006
2	Cancer VaccinesIBA 01/2021 - 09/2010
2	AntigensIBA 01/2021 - 01/2015
2	Concanavalin AIBA 01/2013 - 09/2004
2	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2013 - 10/2012
2	Immunoglobulin G (IgG)IBA 10/2012 - 03/2009
2	Antineoplastic Agents (Antineoplastics)IBA 04/2012 - 05/2008
2	ChemokinesIBA 01/2012 - 05/2005
2	VaccinesIBA 01/2010 - 06/2006
2	Fas Ligand Protein (Fas Ligand)IBA 05/2005 - 09/2003
2	Proteins (Proteins, Gene)FDA Link 04/2005 - 12/2003
1	Alkylating AgentsIBA 01/2022
1	Telmisartan (Micardis)FDA Link 07/2021
1	afliberceptIBA 07/2021
1	Chondroitin Sulfates (Chondroitin Sulfate)IBA 01/2021
1	Bacterial AntigensIBA 01/2021
1	PolyethyleneimineIBA 01/2021
1	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2021
1	Macrophage Colony-Stimulating FactorIBA 01/2018
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2018
1	Interleukin-1 (Interleukin 1)IBA 01/2018
1	Granulocyte Colony-Stimulating Factor (G-CSF)IBA 01/2018
1	Interleukin-6 (Interleukin 6)IBA 01/2018
1	Interleukin-18 (Interleukin 18)IBA 05/2017
1	sipuleucel-T (APC8015)FDA Link 09/2015
1	IpilimumabIBA 09/2015
1	Dinoprostone (PGE2)FDA Link 09/2015
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 09/2015
1	Interleukin-7 (Interleukin 7)IBA 01/2015
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2015
1	Tyrosine Kinase InhibitorsIBA 01/2014
1	Biomarkers (Surrogate Marker)IBA 01/2014
1	Poly I-CIBA 01/2013
1	TNF-Related Apoptosis-Inducing LigandIBA 01/2013
1	Neutralizing AntibodiesIBA 01/2013
1	Immunoglobulin E (IgE)IBA 10/2012
1	Methacholine Chloride (Methacholine)FDA Link 10/2012
1	taxaneIBA 04/2012
1	Indicators and Reagents (Reagents)IBA 04/2012
1	Paclitaxel (Taxol)FDA LinkGeneric 04/2012
1	SeptinsIBA 04/2012
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2012
1	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 10/2011

Therapy/Procedure

12	Immunotherapy 09/2015 - 09/2003
2	Injections 07/2021 - 01/2003
2	Therapeutics 03/2010 - 09/2009
1	Re-Irradiation 01/2022
1	Intravitreal Injections 07/2021
1	Liver Transplantation 01/2019
1	Transplantation 09/2015
1	Subcutaneous Injections 01/2015